PIN Pharma is a pre-IND stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants), for immune modulation in cancer therapy.
PIN Pharma, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://www.pinpharma.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address3960 Broadway STE 620, NY, 10032New YorkUnited States
3960 Broadway STE 620, NY, 10032
New York
United States
Contact Number+1 212-543-2583
+1 212-543-2583
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/pin-pharma” connections=”true” suffix=””]
The Companys technology primes the innate immune system to modulate adaptive immunity thereby generating and expanding antigen-specific cytotoxic T-cells in vivo.
NGN Capital led a $6.75 Mn Series A financing of PIN Pharma, Inc. William Gedale, Senior Advisor of NGN Capital, and Dr. Ivica Cerina, Partner of NGN Capital, serve as chairman and member of the board of directors, respectively.